The publicly disclosed pre-clinical data for the various Mtf and Mtfp studies is very exciting. Bioasis and/or their collaborators have shown efficacy in brain cancer models, LSD models, siRNA, etc., showing that Mtf/Mtfp can be attached to antibodies, siRNAs, enzymes, or other compounds and achieve therapeutic effects.

However, one weakness is that there has not been a standardized animal model methodology applied to all of the Mtf/Mtfp variants to assess brain transport. The studies have been done in different mouse models, in different labs/locations, by different people, using different experimental protocols, using different endpoints, using different lengths of treatment, etc.

One huge advantage of the proposed non-human primate (NHP) studies, as I understand it, is that a panel of 8 candidates will be assessed more or less side by side using a standardized protocol to assess brain transport of a particular drug. By controlling for as many variables as they can, these biOasis NHP studies will be extremely informative to determine the relative efficacy of Mtf/Mtfp with different families of molecules (enzymes, antibodies, siRNAs, other drugs). Also, it may show that certain antibodies are more amenable to Mtf/Mtfp than other antibodies, or certain enzymes are more amendable to Mtf/Mtfp than other enzymes, etc. It sounds like a huge opportunity to develop a side by side comparison of 8 promising targets to really find out which types of molecules or specific molecules are increasing their brain transport the most by the addition of Mtf/Mtfp.

BearDownAZ